CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Stopped Corporate decision to discontinue work in advanced chronic kidney disease

Conditions

• Chronic Kidney Diseases
• Pruritus

Interventions

• DRUG: Difelikefalin 1 mg Oral Tablet
• DRUG: Placebo Oral Tablet

Sponsor

Cara Therapeutics, Inc.